precisionmedicineonline4h
International Working Group Says Biomarkers Aren't Enough to Diagnose Alzheimer's
In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...
BrainTransporter™ dramatically improves antibody delivery to the brain
BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the ...
Le Lézard7h
BrainTransportertm dramatically improves antibody delivery to the brain
BioArctic AB (publ) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in ...
pharmaphorum9h
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
Le Lézard13h
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
BioArctic AB (publ) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET. In conjunction to the report, BioArctic invites ...